AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7794700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 515
Study 7794700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 515
Study 7794700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study 2801224 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP test for bacteriuria
Number of subjects: 0
Study 2801224 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (trimethoprim) given as single dose or as a conventional 7-day regime
Number of subjects: 0
Study 2801224 — intervention group
Group type: COMPARATOR
Intervention: Conventional urine culture
Number of subjects: 0
Study 794090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% solution of N-monochloroglycine (GK-101) applied under pressure
Number of subjects: 61
Study 794090 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution of normal saline
Number of subjects: 61
Study 794090 — intervention group
Group type: EXPERIMENTAL
Intervention: GK-101 solution in conjunction with the pump system
Number of subjects: 61
Study 794090 — intervention group
Group type: EXPERIMENTAL
Intervention: GK-101 solution
Number of subjects: 61
Study 31744496 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B/A1 ratio
Number of subjects: 2256
Study 31744496 — intervention group
Group type: COMPARATOR
Intervention: Framingham Risk Score
Number of subjects: 2256
Study 31744496 — intervention group
Group type: COMPARATOR
Intervention: TC/HDL-c
Number of subjects: 2256
Study 29710336 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF‐23 concentration in the top quartile
Number of subjects: 4947
Study 29710336 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF‐23 concentration
Number of subjects: 4947
Study 27363407 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone-impregnated nasal dressing
Number of subjects: 80
Study 27363407 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked nasal dressing
Number of subjects: 80
Study 25247897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with dexmedetomidine 1 μg/kg (Group I - BD)
Number of subjects: 40
Study 25247897 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (Group II - B)
Number of subjects: 40
Study 22747318 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy (EDS)
Number of subjects: 469
Study 22747318 — intervention group
Group type: COMPARATOR
Intervention: Basic dissemination strategy (BDS)
Number of subjects: 469
Study 19935122 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eye drops, twice daily for 3 days
Number of subjects: 150
Study 19935122 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3%, 1 drop every 2 hours for 2 days then 4 times daily for 5 days
Number of subjects: 150
Study 17687151 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (oxaliplatin + FU/LV)
Number of subjects: 1508
Study 17687151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-containing regimens
Number of subjects: 1508
Study 17687151 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (CR)
Number of subjects: 1508
Study 17687151 — intervention group
Group type: COMPARATOR
Intervention: Multimodality approach (CR)
Number of subjects: 1508
Study 16114087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 0
Study 16114087 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 12096449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural treatment combined with interventions designed to improve treatment compliance
Number of subjects: 40
Study 12096449 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐behavioural treatment
Number of subjects: 40
Study 10545734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine sonography with a 20‐MHz flexible catheter‐based high‐resolution real‐time miniature transducer
Number of subjects: 39
Study 10545734 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal sonography
Number of subjects: 39
Study 7821126 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 14
Study 2297107 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural fentanyl infusion
Number of subjects: 20
Study 2297107 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous fentanyl infusion
Number of subjects: 20
Study 772461 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 22
Study 772461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31280470 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 70 µg/day
Number of subjects: 86
Study 31280470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 28364864 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribulus terrestris (TT)
Number of subjects: 180
Study 28364864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 26525625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 60
Study 26525625 — intervention group
Group type: COMPARATOR
Intervention: Ethylmethylhydroxypyridine succinate
Number of subjects: 60
Study 21909736 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enoxaparin
Number of subjects: 3365
Study 21909736 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin
Number of subjects: 3365
Study 21909736 — intervention group
Group type: COMPARATOR
Intervention: 20 mg enoxaparin (in-hospital)
Number of subjects: 3365
Study 21909736 — intervention group
Group type: COMPARATOR
Intervention: 40 mg enoxaparin (in-hospital)
Number of subjects: 3365
Study 21335754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique (UG)
Number of subjects: 12
Study 21335754 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation technique (NS)
Number of subjects: 12
Study 19896082 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF plus plerixafor
Number of subjects: 298
Study 19896082 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus G-CSF
Number of subjects: 298
Study 17040303 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake removal of LMA (Gp A)
Number of subjects: 120
Study 17040303 — intervention group
Group type: COMPARATOR
Intervention: Deep removal of LMA (Gp D)
Number of subjects: 120
Study 12554339 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular flap from the anterior sheath of the abdominal rectus muscle
Number of subjects: 91
Study 12554339 — intervention group
Group type: COMPARATOR
Intervention: Tension-free hernioplasty with mesh umbrella plug
Number of subjects: 91
Study 10858984 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin test
Number of subjects: 26
Study 10858984 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 9336579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 0
Study 9336579 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 0
Study 9336579 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil
Number of subjects: 0
Study 8462582 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal orientation of chest radiographs
Number of subjects: 60
Study 8462582 — intervention group
Group type: COMPARATOR
Intervention: Rotated orientation of chest radiographs
Number of subjects: 60
Study 8462582 — intervention group
Group type: COMPARATOR
Intervention: Unlimited viewing time for rotated images
Number of subjects: 60
Study 3535053 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 28
Study 3535053 — intervention group
Group type: COMPARATOR
Intervention: Parenteral therapy
Number of subjects: 28
Study 31891833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of alcohol (mean BAC: 0.03 g/dL) during moped riding simulation
Number of subjects: 24
Study 31891833 — intervention group
Group type: COMPARATOR
Intervention: Sober condition (no alcohol) during moped riding simulation
Number of subjects: 24
Study 30060256 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban
Number of subjects: 1050
Study 30060256 — intervention group
Group type: COMPARATOR
Intervention: dalteparin
Number of subjects: 1050
Study 30060256 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban (in patients with gastrointestinal cancer)
Number of subjects: 1050
Study 30060256 — intervention group
Group type: COMPARATOR
Intervention: dalteparin (in patients with gastrointestinal cancer)
Number of subjects: 1050
Study 28393633 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP‐1103 (CHF5074)
Number of subjects: 48
Study 28393633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26266949 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine awareness and knowledge assessment among teachers
Number of subjects: 339
Study 26266949 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation of the HPV vaccine
Number of subjects: 339
Study 26266949 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to HPV vaccine acceptance
Number of subjects: 339
Study 23974210 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour partial sleep deprivation at the end of the night (SDE)
Number of subjects: 12
Study 23974210 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour partial sleep deprivation at the beginning of the night (SDB)
Number of subjects: 12
Study 23974210 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep night
Number of subjects: 12
Study 21080861 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 501
Study 21080861 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 501
Study 18420099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin (10/20 mg/day) + Niacin (titrated to 2 g/day)
Number of subjects: 1220
Study 18420099 — intervention group
Group type: COMPARATOR
Intervention: Niacin (titrated to 2 g/day)
Number of subjects: 1220
Study 18420099 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe/Simvastatin (10/20 mg/day)
Number of subjects: 1220
Study 17063993 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin group (17 patients)
Number of subjects: 41
Study 17063993 — intervention group
Group type: COMPARATOR
Intervention: Glucose group (24 patients)
Number of subjects: 41
Study 12766689 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral reinnervation of facial muscles in patients with complete facial palsy
Number of subjects: 15
Study 12766689 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 15
Study 10837304 — intervention group
Group type: EXPERIMENTAL
Intervention: [57Fe]ferrous fumarate
Number of subjects: 17
Study 10837304 — intervention group
Group type: COMPARATOR
Intervention: [57Fe]ferric pyrophosphate
Number of subjects: 17
Study 10837304 — intervention group
Group type: EXPERIMENTAL
Intervention: [57Fe]ferrous fumarate with 25 mg ascorbic acid
Number of subjects: 17
Study 10837304 — intervention group
Group type: EXPERIMENTAL
Intervention: [57Fe]ferrous fumarate with 50 mg ascorbic acid
Number of subjects: 17
Study 9052312 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg clonidine intravenously
Number of subjects: 60
Study 9052312 — intervention group
Group type: COMPARATOR
Intervention: Saline or placebo (control)
Number of subjects: 60
Study 9052312 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 60
Study 8463920 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal tea preparation
Number of subjects: 68
Study 8463920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 2858214 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 6
Study 2858214 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 6
Study 2858214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31110087 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Number of subjects: 180
Study 31110087 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgery (inspection of the shoulder joint)
Number of subjects: 180
Study 30247579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 361
Study 30247579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 30247579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole and Placebo
Number of subjects: 361
Study 27899107 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplugged program (12 weekly classes)
Number of subjects: 2185
Study 27899107 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2185
Study 24557083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 1276
Study 24557083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1276
Study 23233798 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 8 weeks
Number of subjects: 20
Study 23233798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 20416290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LM) intervention, n=15
Number of subjects: 30
Study 20416290 — intervention group
Group type: COMPARATOR
Intervention: Usual care control, n=15
Number of subjects: 30
Study 18589473 — intervention group
Group type: COMPARATOR
Intervention: Invisible flicker adaptation
Number of subjects: 0
Study 18589473 — intervention group
Group type: COMPARATOR
Intervention: 20Hz flicker
Number of subjects: 0
Study 18589473 — intervention group
Group type: EXPERIMENTAL
Intervention: 5Hz flicker adaptation
Number of subjects: 0
Study 15657607 — intervention group
Group type: EXPERIMENTAL
Intervention: Information provided to participants in the ABIS Study
Number of subjects: 293
Study 15657607 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of information regarding high-risk identification, potential prevention, and future questionnaires
Number of subjects: 293
Study 12098596 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberiotoxin (10-7 M)
Number of subjects: 0
Study 12098596 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (10-10-10-4 M)
Number of subjects: 0
Study 11020195 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive early antigen (EA) serology
Number of subjects: 111
Study 11020195 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative EA and viral capsid antigen (VCA) serology
Number of subjects: 111
Study 11020195 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative EA and positive VCA serology
Number of subjects: 111
Study 11020195 — intervention group
Group type: EXPERIMENTAL
Intervention: Serology for EA
Number of subjects: 111
Study 11020195 — intervention group
Group type: EXPERIMENTAL
Intervention: Serology for VCA
Number of subjects: 111
Study 9049793 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable membrane (polyglactin-910)
Number of subjects: 11
Study 9049793 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-resorbable membrane (e-PTFE)
Number of subjects: 11
Study 9049793 — intervention group
Group type: COMPARATOR
Intervention: Both membrane types
Number of subjects: 11
Study 8341774 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated telephoned reminders
Number of subjects: 143
Study 8341774 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephoned reminders)
Number of subjects: 143
Study 3565796 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (2 mg/kg)
Number of subjects: 17
Study 3565796 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (5 ml) - Control
Number of subjects: 17
Study 29800466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 65
Study 29800466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 26638126 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Contingent (EC) reinforcement
Number of subjects: 88
Study 26638126 — intervention group
Group type: COMPARATOR
Intervention: Extended Noncontingent (EN) reinforcement
Number of subjects: 88
Study 23982026 — intervention group
Group type: EXPERIMENTAL
Intervention: Light sedation (1.26 ± 0.35 μg/mL)
Number of subjects: 14
Study 23982026 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sedation (2.52 ± 0.71 μg/mL)
Number of subjects: 14
Study 23982026 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (regardless of sedation depth)
Number of subjects: 14
Study 23982026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Number of subjects: 14
Study 22771238 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26576 (100 mg b.i.d.) for 3 weeks
Number of subjects: 67
Study 22771238 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26576 flexible dose (100-300 mg b.i.d.) for 3 weeks
Number of subjects: 67
Study 22771238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 19995834 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Knowledge Questionnaire (MSKQ)
Number of subjects: 54
Study 19995834 — intervention group
Group type: EXPERIMENTAL
Intervention: Information aid
Number of subjects: 54
Study 19995834 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 54
Study 19995834 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease duration
Number of subjects: 54
Study 18345715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 95
Study 18345715 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 95
Study 15910382 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 mAbs
Number of subjects: 287
Study 15910382 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclosporine (CYS)
Number of subjects: 287
Study 12656538 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based bedside personal computer
Number of subjects: 8
Study 12656538 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic workstation
Number of subjects: 8
Study 10555907 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 219
Study 10555907 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 125 mg once daily
Number of subjects: 219
Study 10555907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 9019639 — intervention group
Group type: EXPERIMENTAL
Intervention: quinapril and hydrochlorothiazide (HCTZ)
Number of subjects: 225
Study 9019639 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol and hydrochlorothiazide
Number of subjects: 225
Study 9019639 — intervention group
Group type: EXPERIMENTAL
Intervention: quinapril and hydrochlorothiazide
Number of subjects: 225
Study 9019639 — intervention group
Group type: COMPARATOR
Intervention: quinapril and hydrochlorothiazide and metoprolol and hydrochlorothiazide
Number of subjects: 225
Study 2063700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension reduction subscale of the Alcohol Expectancy Questionnaire (AEQ)
Number of subjects: 0
Study 2063700 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-stress situation
Number of subjects: 0
Study 2063700 — intervention group
Group type: COMPARATOR
Intervention: Nonstress control situation
Number of subjects: 0
Study 30982298 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with consultation (animated educational video + conventional consultation)
Number of subjects: 0
Study 30982298 — intervention group
Group type: COMPARATOR
Intervention: Conventional consultation (without video)
Number of subjects: 0
Study 28264983 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 0
Study 28264983 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 25880964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (people who inject drugs)
Number of subjects: 2413
Study 23323566 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric contraction modulation treatment (TANTALUS-DIAMOND)
Number of subjects: 40
Study 21253821 — intervention group
Group type: EXPERIMENTAL
Intervention: Families and Schools Together (FAST) program (intervention group, 140 parents)
Number of subjects: 282
Study 21253821 — intervention group
Group type: COMPARATOR
Intervention: Control group (142 parents)
Number of subjects: 282
Study 19579907 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 32
Study 19579907 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list condition (WL)
Number of subjects: 32
Study 17551296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 17551296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15356042 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg) once daily for 6 months
Number of subjects: 80
Study 15356042 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 6 months
Number of subjects: 80
Study 11430964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal gas drain
Number of subjects: 225
Study 11430964 — intervention group
Group type: COMPARATOR
Intervention: Dummy drain (Control)
Number of subjects: 225
Study 9520555 — intervention group
Group type: EXPERIMENTAL
Intervention: item‐by‐item knowledge of responses
Number of subjects: 73
Study 9520555 — intervention group
Group type: EXPERIMENTAL
Intervention: answer‐until‐correct
Number of subjects: 73
Study 9520555 — intervention group
Group type: EXPERIMENTAL
Intervention: delayed feedback
Number of subjects: 73
Study 9520555 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 73
Study 7863489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (250 mg/kg)
Number of subjects: 85
Study 7863489 — intervention group
Group type: COMPARATOR
Intervention: Control (no ascorbic acid)
Number of subjects: 85
Study 2530191 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 50 mg daily
Number of subjects: 50
Study 2530191 — intervention group
Group type: COMPARATOR
Intervention: Minocycline 100 mg daily (50 mg twice daily)
Number of subjects: 50